SII’s Covovax receives emergency approval for children aged 12-17 years
NEW DELHI: India’s drug regulator has granted restricted emergency use authorisation to Serum Institute’s COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions.
Novavax in global trials has demonstrated more than 90% efficacy. @SerumInstIndia's brand Covovax has completed bridging studies in India & has been granted Emergency Use Authorisation by DCGI for adults & for children above the age of 12. Younger age groups will follow shortly.
— Adar Poonawalla (@adarpoonawalla) March 9, 2022
Confirming the DCGI approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted:”@SerumInstIndia’s brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.” It is the fourth vaccine to receive the regulator’s nod for use among those below 18 years. However, only one vaccine –Bharat Biotech’s Covaxin– is used for the 15-18 years age group in the vaccination drive in the country after the government approval.
The Drugs Controller General Of India’s (DCGI) approval comes after the Subject Expert Committee on COVID-19 of the CDSCO last week recommended granting emergency use authorisation (EUA) to Covovax for those aged 12 to 17.
The government has still not taken a decision on vaccinating those aged below 15 years and the health ministry has consistently said that additional need for vaccination and inclusion of population for vaccination are examined constantly.
In the EUA application to DCGI on February 21, Prakash Kumar Singh, director (government and regulatory affairs) at SII had stated that the data from two studies on about 2707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group of children.
Singh in his application had said,”this approval will not only be beneficial for our country alone, but will benefit the entire world, fulfilling our prime minister’s vision of ‘making in India for the world’.
“In line with the philosophy of our CEO, Dr Adar C Poonawalla, we are sure that Covovax will play an important role to protect the children of our country and the world at large against COVID-19 disease and will keep our national flag flying high globally”, according to an official source.
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28. It has not yet been included in the country’s vaccination drive.
The DCGI on February 21 granted restricted EUA to Biological E’s COVID-19 vaccine Corbevax for the 12-18 years age group subject to certain conditions.
Covovax is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorisation and also granted emergency use listing by WHO on December 2017, 2020. ZyCov-D is the first vaccine cleared by India’s drug regulator for inoculation of those aged 12 years and above in August last year. Indigenously developed Covaxin received approval for emergency use in 12 to 18 in December last year.
Source: Press Trust of India